Cleared Special

K260320 - Lunit INSIGHT MMG (v1.1.10) (FDA 510(k) Clearance)

Class II Radiology device cleared through the Special 510(k) pathway - typically does not require clinical trials.

K260320 · Lunit, Inc. · Radiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2026
Decision
83d
Days
Class 2
Risk

K260320 is an FDA 510(k) clearance for the Lunit INSIGHT MMG (v1.1.10). Classified as Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer (product code QDQ), Class II - Special Controls.

Submitted by Lunit, Inc. (Seoul, KR). The FDA issued a Cleared decision on April 23, 2026 after a review of 83 days - a notably fast clearance cycle.

This device falls under the Radiology FDA review panel, regulated under 21 CFR 892.2090 - the FDA radiology and imaging software oversight framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Lunit, Inc. devices

Submission Details

510(k) Number K260320 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 30, 2026
Decision Date April 23, 2026
Days to Decision 83 days
Submission Type Special
Review Panel Radiology (RA)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
24d faster than avg
Panel avg: 107d · This submission: 83d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code QDQ Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 892.2090
Definition A Radiological Computer Assisted Detection And Diagnostic Software For Suspected Lesions Is An Image Processing Device Intended To Aid In The Detection, Localization, And Characterization Of Lesions Suspicious For Cancer On Acquired Medical Images (e.g., Mammography , Mr, Ct, Ultrasound, Radiography). The Device Detects, Identifies And Characterizes Lesions Suspicious For Cancer Based On Features Or Information Extracted From The Images, And May Provide Information About The Presence, Location, And Characteristics Of The Lesion To The User. Primary Diagnostic And Patient Management Decisions Are Made By The Clinical User.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Radiology devices follow this clearance model.

Regulatory Peers - QDQ Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer

All 33
Devices cleared under the same product code (QDQ) and FDA review panel - the closest regulatory comparables to K260320.
DeepHealth ProstateAI
K253682 · Quantib B.V. · Apr 2026
Lunit INSIGHT DBT (V1.2)
K253796 · Lunit, Inc. · Mar 2026
Median LCS (internal name) / eyonis LCS (trade name) (1.0)
K251474 · Median Technologies · Feb 2026
Saige-Dx
K251873 · DeepHealth, Inc. · Aug 2025
Genius AI Detection 2.0
K243341 · Hologic, Inc. · Jul 2025
MammoScreen® (4)
K243679 · Therapixel · Jul 2025